• An innovative microRNA-based test (ColoFast), designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).
    • Identifying a higher number of individuals affected by preliminary stages of colon cancer (such as advanced adenomas)
    • Cutting-edge biomarkers, proving a higher reduction in colon cancer mortality than current competitors in the market.
    • Better compliance than fecal tests.
    • Addressing a clear unmet medical need in a large and expanding target population.
    • Saving lives through early detection




Comments are closed, but trackbacks and pingbacks are open.